Calls for generic drug giant Mylan to change the pricing of its lifesaving epinephrine auto-injector EpiPen have gained support from a third senator, further reigniting a broader national debate about the cost of prescription drugs.

Sen. Richard Blumenthal, D-Conn., joined Sens. Charles Grassley, R-Iowa, and Amy Klobuchar, D-Minn., in questioning why the cost of the auto-injector has risen from just under $60 when Mylan acquired it in 2007 to about $600 for a pair now.

In a news release, Mr. Blumenthal demanded Mylan “take immediate action to lower the price of EpiPens for all Americans that rely on this product for their health and safety,” adding that his office has been contacted by dozens of constituents “who urgently require your life-saving product but fear that its skyrocketing price has put it out of reach.”

Mr. Grassley on Monday sent a letter to Cecil-based Mylan CEO Heather Bresch asking her to explain the price increases for the auto-injector, which is used for emergency treatment of severe food or bee sting allergies, and Ms. Klobuchar called on the Federal Trade Commission to investigate whether Mylan had moved to block competitors from entering the epinephrine injection market.

Advertise with us

The scrutiny comes at a time of heightened attention and criticism of pharmaceutical companies’ product pricing, an issue brought to the fore last fall when then-Turing Pharmaceutical CEO Martin Shkreli proposed increasing the price of its drug to treat the parasitic infection toxoplasmosis from $13.50 a pill to $750.

About the same time, but receiving less attention, a report by Bloomberg Business Week described how Mylan’s 2007 acquisition of EpiPen from Merck KGaA turned a drug with yearly revenues of $200 million into “a $1 billion-a-year product that clobbers its rivals and provides about 40 percent of Mylan’s operating profits.”

One possible rival, Sanofi US, voluntarily recalled its Auvi-Q epinephrine injector last fall due to dosage accuracy problems which the company said “may include failure to deliver drug.”

With EpiPen’s current “near-monopoly on the market,” Fortune reported this week that Mylan’s auto-injector has netted annual sales of more than $1.3 billion.

S&P Capital IQ analyst Jeffrey Loo does not expect the outrage over EpiPen’s price increase will have a long-term impact on Mylan or the drug industry. He said that high drug prices “have always been a contentious issue” and that Congress routinely holds hearings whenever drug prices surge.

Advertise with us

“Mylan’s the latest one with EpiPen. Clearly, from a public relations view, it’s a black cloud,” Mr. Loo said. “But they have a virtual monopoly in that marketplace, so it’s not going to impact their sales. In time, I think this will blow over.”

He said Mylan benefited not only from the Auvi-Q recall as well as rival Teva’s failure to launch a competing version of the drug. Mylan shares closed Tuesday down $2.28, nearly five percent, at $45.62.

During the company’s Aug. 9 earnings call, Mylan CEO Heather Bresch defended the EpiPen’s pricing, saying, “If you look on an annual basis, as a lifesaving drug, to have a WAC [wholesale acquisition cost] price at just under $600, I think that you can see it falls as not an expensive product.”

She also noted the emergence of high-deductible insurance plans has meant that some customers’ plans leave them responsible for the EpiPen’s full cost instead of a lower copayment.

As a result, “As employers shift more cost to employees and make that everything’s got to come out of pocket before you hit your deductible is where you’re seeing a lot of noise around EpiPen.”

Advertise with us

Mylan did not return a phone message Tuesday seeking comment. However, in a statement posted on the company’s website Monday, Mylan officials said that in 2015 nearly 80 percent of commercially insured patients using a special savings card got the auto-injector at no cost.

They also pointed to one program which has distributed more than 700,000 EpiPen auto-injectors free to more than 65,000 schools and another which offers consumers up to $100 off for a two-pack carton.

Although Pennsylvania does not require that school districts keep EpiPens on-site, “Any school can apply and if a school physician writes a script, it’s provided free of charge” by Mylan, said Kathy Verbel, the Monroe County-based president-elect of the Pennsylvania Association of School Nurses and Practitioners.

She added that Mylan “also provides educational material” for using the injectors.

EpiPen is the clear leader in Mylan’s specialty drug segment, where net sales in the second quarter this year increased 33 percent to $402.5 million compared with the same three-month period in 2015.

Advertise with us

Ms. Bresch said during the Aug. 9 earnings call that EpiPen “will be a very, very important product for a very long time” while adding that “as we continue to grow… EpiPen from a true dollar contribution will just continue to shrink” so the company is not overly reliant on the EpiPen brand.

“But I can tell you that there’s every bit of focus on the role EpiPen plays in the lives and saving lives and then getting to as many patients as we possibly can,” she said.

Steve Twedt: stwedt@post-gazette.com or 412-263-1963. Len Boselovic: lboselovic@post-gazette.com or 412-263-1941.